Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.31 in the first quarter of 2025, which improved 14.9% year over year. The figure topped the Zacks Consensus Estimate by 3.2%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP loss per share for the quarter was 66 cents, against EPS of 59 cents in the p ...

Integer (ITGR) Q1 2025 Earnings Call April 25, 2025 12:52 AM ET Company Participants Sanjiv Arora - SVP, Strategy, Business Development and IRJoseph Dziedzic - President & CEOPayman Khales - COODiron Smith - Executive VP & CFORichard Newitter - Managing DirectorNathan Treybeck - Equity Research Vice PresidentAndrew Cooper - VP - Equity ResearchJoanne Wuensch. - Managing DirectorSuraj Kalia - Managing Director Conference Call Participants Brett Fishbin - Vice President & Equity Research AnalystCraig Bijou - ...

Integer Holdings Corporation First Quarter 2025 Earnings Conference Call April 24, 2025 Integer Holdings Corporation First Quarter 2025 Earnings Conference Call 9 a.m. Eastern Time, April 24, 2025 Management Attendees: Diron Smith Executive Vice President, Chief Financial Officer Sanjiv Arora Senior Vice President, Strategy, Business Development & Investor Relations ITGR: 1Q25 Earnings Conference Call | April 24, 2025 | Page 2 Joe Dziedzic President, Chief Executive Officer Payman Khales President and CEO E ...

Financial Data and Key Metrics Changes - In Q1 2025, Integer Holdings Corporation reported sales of $437 million, reflecting a 7% year-over-year increase on a reported basis and a 6% increase on an organic basis [20][13] - Adjusted operating income grew by 14%, with adjusted net income reaching $46 million, up 19% year-over-year, and adjusted earnings per share totaled $1.31, up 15% from the same period last year [22][25] - The company reiterated its sales outlook for 2025, expecting reported growth of 8% to 10% and organic growth of 6% to 8% [14][32] Business Line Data and Key Metrics Changes - Cardiovascular sales increased by 17% in Q1 2025, driven by new product ramps in electrophysiology and contributions from recent acquisitions [22] - Cardiac rhythm management and neuromodulation sales grew by 2% in Q1 2025, with expectations of low to mid-single-digit growth for the full year [23][24] Market Data and Key Metrics Changes - The company expects CNV sales to grow in the mid-teens compared to 2024, while CRM and N sales are projected to grow low to mid-single digits [23][24] - The order book increased to approximately $800 million, reflecting strong demand and new product introductions [82] Company Strategy and Development Direction - Integer Holdings Corporation is focused on building differentiated capabilities and collaborating closely with customers to deliver innovative medical device technologies [12] - The company completed two tuck-in acquisitions, enhancing its service offerings and expanding its capabilities in proprietary coating technologies [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong sales growth, citing high visibility to customer demand and ramping programs in high-growth markets [14][40] - The company is managing its debt leverage within a target range of 2.5% to 3.5% times EBITDA, with a strategic refinancing completed to reduce interest expenses [29][30] Other Important Information - The company raised its adjusted net income outlook by $10 million, reflecting the impact of interest expense savings [34] - Cash flow from operations increased by 35% year-over-year to $31 million, with free cash flow improving by $12 million from the prior year [28][37] Q&A Session Summary Question: Impact of tariffs on adjusted operating income - Management confirmed the estimated impact of tariffs for 2025 remains between $1 to $5 million, with efforts to minimize this impact [44][49] Question: Deceleration in CRM segment growth - Management noted fewer selling days as a headwind and expects mid-single-digit growth in the CRM segment moving forward [50][56] Question: Growth in electrophysiology - Management stated that electrophysiology continues to outgrow the market, contributing significantly to overall cardiovascular growth [60][62] Question: Customer inventory levels and potential impacts - Management indicated no significant changes in customer ordering patterns related to tariffs, viewing any potential changes as timing issues [128][130] Question: Resilience in a recessionary environment - Management expressed confidence in the company's resilience during economic downturns, noting that most therapies supported are not elective [142][145]

Integer (ITGR) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 3.15%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.46 per share when it actually produced earnings of $1.43, delivering a surprise of -2.05%. Over the last fou ...

EXHIBIT 99.1 Integer Holdings Corporation Reports First Quarter 2025 Results ~ Strong start to the year with 1Q25 financial results ~ ~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ "Integer started the year off strong with first quarter 2025 sales growing at 7% year-over-year as we continue to execute our strategy by launching new products and adding capabilities in targeted growth markets. Integer also delivered 14% adjusted operating income growth," said Jos ...

Leadership Transition - Joseph Dziedzic will retire as President and CEO of Integer Holdings Corporation effective October 24, 2025, and will step down from the Board of Directors [1] - Payman Khales, currently the Chief Operating Officer, will assume the role of President and CEO and join the Board at that time [1] - To ensure a smooth transition, Dziedzic will serve as an advisor to the company until March 31, 2026 [1] Achievements and Strategy - Dziedzic's leadership over the past eight years has driven significant growth and value creation for Integer, focusing on high-growth markets and unmet patient needs [2] - Under Dziedzic, the company accelerated investments in differentiated technologies and implemented the Integer Production System to enhance manufacturing consistency [2] - Integer is currently achieving above-market organic sales growth with expanding margins, positioning the company for continued growth [2] Incoming CEO Profile - Payman Khales has been with Integer since 2018, initially as President of the Cardio & Vascular business, where he successfully doubled sales in seven years [3][5] - As COO, Khales has overseen both of Integer's business units and has been integral to the development and execution of the company's strategy [3][5] - Khales holds an Executive MBA from Indiana University's Kelley School of Business and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal [6] Company Overview - Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving cardiac rhythm management, neuromodulation, and cardio and vascular markets [7] - The company is committed to enhancing patient lives through innovative, high-quality products and solutions, with brands including Greatbatch Medical and Lake Region Medical [7]

Core Insights - Integer Holdings Corporation reported a strong start to 2025 with a 7% year-over-year sales growth and a 14% increase in adjusted operating income [1][5] - The company raised its adjusted net income growth outlook to a range of 19% to 26% for 2025, while maintaining a sales growth forecast of 8% to 10% [1][4] Financial Performance - First quarter 2025 sales reached $437 million, up from $407.8 million in the same period last year, reflecting a 7% increase [5][18] - GAAP operating income increased by 28% to $50 million, while non-GAAP adjusted operating income rose by 14% to $71 million [5][37] - GAAP income from continuing operations showed a loss of $22 million, a decrease from a profit of $20.6 million in Q1 2024, primarily due to debt conversion inducement expenses [5][37] - Non-GAAP adjusted net income increased by 19% to $46 million, with adjusted EPS rising to $1.31 from $1.14 [5][41] Product Line Performance - Cardio & Vascular sales increased by 17% year-over-year, driven by new product launches and acquisitions [6] - Cardiac Rhythm Management & Neuromodulation sales grew by 2%, supported by emerging neuromodulation customers [6] - Other Markets sales decreased by 37%, primarily due to the planned exit from the Portable Medical market [6][18] 2025 Outlook - The company updated its 2025 outlook to reflect the impact of a $1 billion convertible note offering, which is expected to reduce interest expenses by $13 million [3][5] - Adjusted operating income for 2025 is projected to be between $331 million and $401 million, reflecting an 11% to 16% increase [4][5] - The leverage ratio as of March 28, 2025, was reported at 3.3 times adjusted EBITDA, with total debt increasing to $1.235 billion [5][12] Leadership Changes - The company announced that Joseph Dziedzic will retire as President and CEO on October 24, 2025, with Payman Khales set to assume the role [20]

Core Insights - Integer (ITGR) is expected to report quarterly earnings of $1.27 per share, reflecting an 11.4% increase year-over-year, with revenues projected at $431.84 million, a 4.1% increase from the previous year [1] - Over the last 30 days, the consensus EPS estimate has been revised upward by 1.6%, indicating a positive reassessment by analysts [1][2] Revenue Estimates - Analysts predict 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' to reach $162.26 million, showing a year-over-year increase of 3.8% [4] - 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' is estimated at $22.58 million, reflecting a significant decline of 22.5% from the prior-year quarter [4] - 'Sales- Medical Sales- Cardio & Vascular' is expected to be $247.02 million, indicating an 11.4% increase compared to the same quarter last year [5] Market Performance - Integer shares have decreased by 1.5% over the past month, contrasting with the Zacks S&P 500 composite's decline of 8.9% [6] - The company holds a Zacks Rank of 3 (Hold), suggesting it is likely to perform in line with the overall market in the near term [6]

Core Viewpoint - Integer Holdings Corporation is addressing the impact of tariffs on its business, estimating a potential effect of $1 to $5 million on full year adjusted operating income due to recent trade policy developments [2][6]. Company Overview - Integer Holdings Corporation (NYSE:ITGR) is a leading contract development and manufacturing organization in the medical device sector, focusing on cardiac rhythm management, neuromodulation, and cardiovascular markets [4]. - The company is recognized as a strategic partner for medical device companies and OEMs, committed to enhancing patient lives through innovative and high-quality products [4]. Financial Impact - The estimated impact of tariffs on Integer's adjusted operating income incorporates both currently applicable tariffs and additional tariffs announced on April 2, which will take effect after a 90-day pause [2]. - The company plans to release its financial and operational results for the first quarter of 2025 on April 24, 2025 [3].